2022215-65-0
2022215-65-0
Chemical Structure
Cobolimab
Synonym(s): TSR-022; GSK4069889
- CAS No.: 2022215-65-0
- Formula:N/A
- Molecular Weight:(142.84 kDa)
IUPAC Name: 2-(1,3-dioxoisoindolin-2-yl)-2-methylpropanoic acid
SMILES: [Cobolimab]
Biological Activity: Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cobolimab | 98.00% | Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.
- [2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. [Content Brief]
- [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. [Content Brief]
